uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.893 | Q34 | What are the names of the genes that are targeted by the drug Naproxen Sodium in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Naproxen Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%naproxen sodium%" OR LOWER(tradeNames_list) LIKE "%naproxen sodium%" OR LOWER(syns_list) LIKE "%naproxen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838129', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838180', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838197', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838214', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838248', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838265', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838282', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838299', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838163', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838095', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838061', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838044', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838231', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838146', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838112', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838078', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.711 | Q34 | What are the names of the genes that are targeted by the drug Asciminib Hydrochloride in the treatment of chronic myelogenous leukemia? | In the context of chronic myelogenous leukemia, the drug Asciminib Hydrochloride targets the gene ABL proto-oncogene 1, non-receptor tyrosine kinase and BCR activator of RhoGEF and GTPase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic myelogenous leukemia%" OR LOWER(efo_term) LIKE "%chronic myelogenous leukemia%") AND (LOWER(drugName) LIKE "%asciminib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%asciminib hydrochloride%" OR LOWER(syns_list) LIKE "%asciminib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_749464', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749466', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749462', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749460', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749459', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_749465', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749463', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase'}, {'UUID': 'DrugTargetsIndication121923_text_749461', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_list': "['Scemblix']", 'syns_list': "['ABL001-AAA', 'Asciminib hydrochloride', 'Scemblix']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'efo_term': 'chronic myelogenous leukemia', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1524 | Q34 | What are the names of the genes that are targeted by the drug Risdiplam in the treatment of spinal muscular atrophy? | In the context of spinal muscular atrophy, the drug Risdiplam targets the gene survival of motor neuron 2, centromeric. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spinal muscular atrophy%" OR LOWER(efo_term) LIKE "%spinal muscular atrophy%") AND (LOWER(drugName) LIKE "%risdiplam%" OR LOWER(tradeNames_list) LIKE "%risdiplam%" OR LOWER(syns_list) LIKE "%risdiplam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072735', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'syns_list': "['RG-7916', 'RG7916', 'RO-7034067', 'RO7034067', 'Risdiplam']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072737', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'syns_list': "['RG-7916', 'RG7916', 'RO-7034067', 'RO7034067', 'Risdiplam']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.109 | Q34 | What are the names of the genes that are targeted by the drug Duloxetine Hydrochloride in the treatment of Chronic pain? | In the context of Chronic pain, the drug Duloxetine Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic pain%" OR LOWER(efo_term) LIKE "%chronic pain%") AND (LOWER(drugName) LIKE "%duloxetine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%duloxetine hydrochloride%" OR LOWER(syns_list) LIKE "%duloxetine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206074', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206122', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206138', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206154', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206186', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206202', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206218', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206250', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206266', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206282', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206298', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206330', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206346', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206362', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206378', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206394', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206410', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206426', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206442', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206458', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206474', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206490', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206234', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206106', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206042', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206010', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205994', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206314', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206170', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206090', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206058', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206026', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1118 | Q34 | What are the names of the genes that are targeted by the drug Levothyroxine Sodium in the treatment of hypothyroidism? | In the context of hypothyroidism, the drug Levothyroxine Sodium targets the gene thyroid hormone receptor alpha and thyroid hormone receptor beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypothyroidism%" OR LOWER(efo_term) LIKE "%hypothyroidism%") AND (LOWER(drugName) LIKE "%levothyroxine sodium%" OR LOWER(tradeNames_list) LIKE "%levothyroxine sodium%" OR LOWER(syns_list) LIKE "%levothyroxine sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924816', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924827', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924830', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924834', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924841', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924844', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924848', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924855', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924858', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924862', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924865', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924872', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924876', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924879', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924883', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924886', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924890', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924893', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924897', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924900', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924904', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924911', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924914', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924918', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924921', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924925', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924932', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924935', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924939', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924942', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924946', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924949', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924953', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924956', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924960', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924963', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924967', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924970', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924974', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924977', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924981', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924984', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924988', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924991', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924995', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924998', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925002', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925005', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925009', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925012', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925016', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925023', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925026', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925030', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925033', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925037', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925040', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925047', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925051', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925054', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925058', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925061', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925065', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925068', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925072', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925075', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925079', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925082', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925086', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925089', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925093', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925096', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925100', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925103', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925107', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925110', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925114', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925117', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925121', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925124', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925128', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925131', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925135', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925138', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925142', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925145', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925019', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924907', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924851', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924823', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924809', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924802', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924799', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925044', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924928', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924869', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924837', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Congenital Hypothyroidism', 'efo_term': 'congenital hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924820', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924813', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924806', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.501 | Q34 | What are the names of the genes that are targeted by the drug Methylphenidate in the treatment of narcolepsy-cataplexy syndrome? | In the context of narcolepsy-cataplexy syndrome, the drug Methylphenidate targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy-cataplexy syndrome%" OR LOWER(efo_term) LIKE "%narcolepsy-cataplexy syndrome%") AND (LOWER(drugName) LIKE "%methylphenidate%" OR LOWER(tradeNames_list) LIKE "%methylphenidate%" OR LOWER(syns_list) LIKE "%methylphenidate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_439366', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439459', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439490', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439521', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439583', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439614', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439645', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439707', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439738', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439769', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439800', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439862', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439893', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439924', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439955', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_439986', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440017', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440048', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440079', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440110', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440141', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440203', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440234', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440265', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440296', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440327', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440389', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440420', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440451', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440482', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440513', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440544', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440575', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440606', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440637', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440668', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_440172', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_439676', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439428', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439304', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439242', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439211', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440358', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_439831', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439552', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439397', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439335', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_439273', 'drugName': 'Methylphenidate', 'tradeNames_list': "['Concerta', 'Cotempla xr-odt', 'Daytrana']", 'syns_list': "['Concerta', 'Methylin', 'MethylphenidateMethylphenidate extended release', 'Prc-063', 'Threo-dl-methylphenidate']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1963 | Q34 | What are the names of the genes that are targeted by the drug Lubiprostone in the treatment of Chronic pain? | In the context of Chronic pain, the drug Lubiprostone targets the gene chloride voltage-gated channel 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic pain%" OR LOWER(efo_term) LIKE "%chronic pain%") AND (LOWER(drugName) LIKE "%lubiprostone%" OR LOWER(tradeNames_list) LIKE "%lubiprostone%" OR LOWER(syns_list) LIKE "%lubiprostone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193410', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193425', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193430', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193435', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193445', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193450', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193455', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193465', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193470', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193460', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193420', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193390', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193385', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193400', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193440', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193415', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193405', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193395', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'syns_list': "['Lubiprostone', 'RU-0211']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1550 | Q34 | What are the names of the genes that are targeted by the drug Daridorexant Hydrochloride in the treatment of insomnia? | In the context of insomnia, the drug Daridorexant Hydrochloride targets the gene hypocretin receptor 2 and hypocretin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%insomnia%" OR LOWER(efo_term) LIKE "%insomnia%") AND (LOWER(drugName) LIKE "%daridorexant hydrochloride%" OR LOWER(tradeNames_list) LIKE "%daridorexant hydrochloride%" OR LOWER(syns_list) LIKE "%daridorexant hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1076447', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076450', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076451', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076452', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076449', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076445', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076443', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076442', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076453', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076448', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR1', 'approvedName': 'hypocretin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076446', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076444', 'drugName': 'Daridorexant Hydrochloride', 'tradeNames_list': "['Quviviq']", 'syns_list': "['ACT-541468A', 'Daridorexant hydrochloride', 'Nemorexant hydrochlorideQuviviq']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sleep Initiation and Maintenance Disorders', 'efo_term': 'insomnia', 'approvedSymbol': 'HCRTR2', 'approvedName': 'hypocretin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.732 | Q34 | What are the names of the genes that are targeted by the drug Dabrafenib in the treatment of neoplasm? | In the context of neoplasm, the drug Dabrafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%dabrafenib%" OR LOWER(tradeNames_list) LIKE "%dabrafenib%" OR LOWER(syns_list) LIKE "%dabrafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752841', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752707', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752743', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752680', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752721', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752722', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752728', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752735', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752736', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752742', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752813', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752750', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752679', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753057', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753038', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752764', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752770', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752771', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752777', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752778', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752784', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752791', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752792', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752798', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752799', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752805', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752812', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752953', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752819', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752820', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752826', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752981', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752693', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752834', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752840', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753075', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752686', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753056', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752854', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752855', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752861', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752862', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752868', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752869', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752875', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752876', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752882', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752883', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752889', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752890', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752896', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752903', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752904', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752910', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752911', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752917', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752918', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752925', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752931', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752932', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752938', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752939', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752945', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752946', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752952', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752763', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752959', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752960', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752966', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752967', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752973', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752974', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752980', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753019', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752827', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752833', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752714', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753018', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752756', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752999', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753000', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753076', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752757', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752847', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752694', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753095', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753094', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_753037', 'drugName': 'Dabrafenib', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib', 'GSK-2118436', 'GSK-2118436A', 'GSK2118436A', 'Gsk2118436']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752897', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752785', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752729', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752701', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752687', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752924', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752806', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752749', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752848', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752700', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752708', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752715', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': "['Tafinlar']", 'syns_list': "['Dabrafenib mesilate', 'Dabrafenib mesylateGSK-2118436 METHANESULFONATE SALT', 'GSK-2118436BGSK-2118436B MESYLATE', 'GSK-2118436B METHANESULFONATE SALTGSK2118436B', 'GSK2118436B, METHANE SULFONATE SALTMETHANE SULFONATE SALT']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.598 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of unipolar depression? | In the context of unipolar depression, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653152', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653245', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653276', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653307', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653369', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653400', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653431', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653493', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653524', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653555', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653586', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653648', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653679', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653710', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653741', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653772', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653803', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653834', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653865', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653896', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653927', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653989', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654020', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654051', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654082', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654113', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654175', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654206', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654237', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654268', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654299', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654330', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654361', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654392', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654423', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654454', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654485', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654516', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654547', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654578', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654609', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654640', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654671', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654702', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654733', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654764', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654795', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654826', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654857', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654888', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654919', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654981', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655012', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655043', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655074', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655105', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655136', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655198', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655229', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655260', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655291', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655322', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655353', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655384', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655415', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655446', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655477', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655508', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655539', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655570', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655601', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655632', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655663', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655694', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655725', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655756', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655787', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655818', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655849', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655880', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655911', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655942', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655973', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656004', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656035', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656066', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_654950', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_653958', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653462', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653214', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653090', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653028', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652997', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_655167', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654144', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_653617', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653338', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653183', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653121', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653059', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1094 | Q34 | What are the names of the genes that are targeted by the drug Testosterone Undecanoate in the treatment of orchitis? | In the context of orchitis, the drug Testosterone Undecanoate targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%orchitis%" OR LOWER(efo_term) LIKE "%orchitis%") AND (LOWER(drugName) LIKE "%testosterone undecanoate%" OR LOWER(tradeNames_list) LIKE "%testosterone undecanoate%" OR LOWER(syns_list) LIKE "%testosterone undecanoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_922039', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922078', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922091', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922104', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922130', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922143', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922156', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922182', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922195', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922208', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922221', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922247', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922260', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922273', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922286', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922299', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922312', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922325', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922338', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922351', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922364', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922390', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922403', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922416', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922429', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922442', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922468', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922481', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922494', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922377', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922169', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922065', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922013', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921987', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921974', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922455', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922234', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922117', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922052', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922026', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922000', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1282 | Q34 | What are the names of the genes that are targeted by the drug Pralsetinib in the treatment of neoplasm? | In the context of neoplasm, the drug Pralsetinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%pralsetinib%" OR LOWER(tradeNames_list) LIKE "%pralsetinib%" OR LOWER(syns_list) LIKE "%pralsetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944300', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944307', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944308', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944311', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944315', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944316', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944319', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944323', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944324', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944327', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944328', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944332', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944335', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944336', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944339', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944340', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944343', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944344', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944347', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944348', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944351', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944355', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944356', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944359', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944360', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944363', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944367', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944368', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944352', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944320', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944304', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944296', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944292', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944291', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944364', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944331', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944312', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944303', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944299', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944295', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1927 | Q34 | What are the names of the genes that are targeted by the drug Avacopan in the treatment of Anti-neutrophil cytoplasmic antibody-associated vasculitis? | In the context of Anti-neutrophil cytoplasmic antibody-associated vasculitis, the drug Avacopan targets the gene complement C5a receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anti-neutrophil cytoplasmic antibody-associated vasculitis%" OR LOWER(efo_term) LIKE "%anti-neutrophil cytoplasmic antibody-associated vasculitis%") AND (LOWER(drugName) LIKE "%avacopan%" OR LOWER(tradeNames_list) LIKE "%avacopan%" OR LOWER(syns_list) LIKE "%avacopan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191851', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'Anti-neutrophil cytoplasmic antibody-associated vasculitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191848', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191859', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'Anti-neutrophil cytoplasmic antibody-associated vasculitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191856', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.574 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of neuralgia? | In the context of neuralgia, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neuralgia%" OR LOWER(efo_term) LIKE "%neuralgia%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638823', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637904', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639522', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638709', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637788', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638363', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637901', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638479', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638133', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638134', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640201', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639743', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637797', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640431', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638016', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638018', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638361', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640434', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638364', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639062', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638027', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637903', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639283', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638131', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639396', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638591', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638594', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640204', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638142', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639629', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637912', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_640212', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638246', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638248', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638821', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640433', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638824', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638832', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638257', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638936', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638938', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638939', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638947', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640546', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639051', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639053', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639054', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640442', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638372', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639166', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639168', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639177', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638478', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639281', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639982', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639284', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639292', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640089', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639398', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639399', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639407', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640088', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639511', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639513', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639514', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640318', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638602', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639626', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639628', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640203', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639637', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638708', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639741', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640316', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639744', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639752', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638717', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639856', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639858', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639859', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639867', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640548', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639971', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639973', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639974', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640557', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640549', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640319', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640097', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640086', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639169', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638476', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637789', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638487', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638593', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638706', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640327', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'postherpetic neuralgia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638019', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637786', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638249', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia, Postherpetic', 'efo_term': 'neuralgia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.74 | Q34 | What are the names of the genes that are targeted by the drug Iloperidone in the treatment of schizophrenia? | In the context of schizophrenia, the drug Iloperidone targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%iloperidone%" OR LOWER(tradeNames_list) LIKE "%iloperidone%" OR LOWER(syns_list) LIKE "%iloperidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_200107', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200122', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200127', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200132', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200142', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200147', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200152', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200162', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200167', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200172', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200177', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200187', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200192', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200197', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200202', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200207', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200212', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200217', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200222', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200227', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200232', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200242', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200247', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200252', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200257', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200262', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200272', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200277', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200282', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200287', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200292', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200297', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200302', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200307', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200312', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200317', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200322', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200327', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200332', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200337', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200342', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200347', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200352', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200357', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200362', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200367', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200372', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200377', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200382', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200387', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200392', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200402', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200407', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200412', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200417', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200422', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200427', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200437', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200442', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200447', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200452', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200457', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200462', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200467', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200472', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200477', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200482', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200487', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200492', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200497', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200502', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200507', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200512', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200517', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200522', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200527', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200532', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200537', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200542', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200547', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200552', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200557', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200562', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200567', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200572', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200577', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200397', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200237', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200157', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200117', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200097', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200087', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200082', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200432', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_200267', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200182', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200137', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200112', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200102', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200092', 'drugName': 'Iloperidone', 'tradeNames_list': "['Fanapt', 'Iloperidone']", 'syns_list': "['HP 873', 'HP-873', 'Iloperidone']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1620 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran Etexilate Mesylate in the treatment of deep vein thrombosis? | In the context of deep vein thrombosis, the drug Dabigatran Etexilate Mesylate targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%deep vein thrombosis%" OR LOWER(efo_term) LIKE "%deep vein thrombosis%") AND (LOWER(drugName) LIKE "%dabigatran etexilate mesylate%" OR LOWER(tradeNames_list) LIKE "%dabigatran etexilate mesylate%" OR LOWER(syns_list) LIKE "%dabigatran etexilate mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092395', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092410', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092415', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092420', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092430', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092435', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092440', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092450', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092455', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092460', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092465', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092475', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092480', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092485', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092490', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092495', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092500', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092505', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092510', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092515', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092520', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092530', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092535', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092540', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092545', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092550', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092560', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092565', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092570', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092575', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092580', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092585', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092590', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092595', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092600', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092605', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092610', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092615', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092620', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092625', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092630', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092635', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092640', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092645', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092650', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092525', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092445', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092405', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092385', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092375', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092370', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092555', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092470', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092425', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092400', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092390', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092380', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1202 | Q34 | What are the names of the genes that are targeted by the drug Albuterol Sulfate in the treatment of Bronchospasm? | In the context of Bronchospasm, the drug Albuterol Sulfate targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bronchospasm%" OR LOWER(efo_term) LIKE "%bronchospasm%") AND (LOWER(drugName) LIKE "%albuterol sulfate%" OR LOWER(tradeNames_list) LIKE "%albuterol sulfate%" OR LOWER(syns_list) LIKE "%albuterol sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936246', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936273', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936282', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936291', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936309', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936318', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936327', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936345', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936354', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936363', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936372', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936390', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936399', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936408', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936417', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936426', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936435', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936444', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936453', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936462', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936471', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936489', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936498', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936507', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936516', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936525', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936543', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936552', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936561', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936570', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936579', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936588', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936480', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936336', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936264', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936228', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936210', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936201', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936534', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936381', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936300', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936255', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936237', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936219', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1685 | Q34 | What are the names of the genes that are targeted by the drug Dapagliflozin Propylene Glycol in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Dapagliflozin Propylene Glycol targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%dapagliflozin propylene glycol%" OR LOWER(tradeNames_list) LIKE "%dapagliflozin propylene glycol%" OR LOWER(syns_list) LIKE "%dapagliflozin propylene glycol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096260', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096269', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096272', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096275', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096281', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096284', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096287', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096293', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096296', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096299', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096302', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096308', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096311', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096314', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096317', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096320', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096323', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096326', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096329', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096332', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096335', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096341', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096344', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096347', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096350', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096353', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096359', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096338', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096290', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096266', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096254', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096248', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096245', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096356', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096305', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096278', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096263', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096257', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096251', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1375 | Q34 | What are the names of the genes that are targeted by the drug Bremelanotide Acetate in the treatment of sexual dysfunction? | In the context of sexual dysfunction, the drug Bremelanotide Acetate targets the gene melanocortin 4 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sexual dysfunction%" OR LOWER(efo_term) LIKE "%sexual dysfunction%") AND (LOWER(drugName) LIKE "%bremelanotide acetate%" OR LOWER(tradeNames_list) LIKE "%bremelanotide acetate%" OR LOWER(syns_list) LIKE "%bremelanotide acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025290', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'sexual dysfunction', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025292', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'sexual dysfunction', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025288', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'sexual dysfunction', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025286', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'sexual dysfunction', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025285', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'mental or behavioural disorder', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025291', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'mental or behavioural disorder', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025289', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'mental or behavioural disorder', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025287', 'drugName': 'Bremelanotide Acetate', 'tradeNames_list': "['Vyleesi (autoinjector)']", 'syns_list': "['Bremelanotide acetate', 'PT 141', 'PT-141', 'Vyleesi']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sexual Dysfunctions, Psychological', 'efo_term': 'mental or behavioural disorder', 'approvedSymbol': 'MC4R', 'approvedName': 'melanocortin 4 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.485 | Q34 | What are the names of the genes that are targeted by the drug Lisdexamfetamine Dimesylate in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Lisdexamfetamine Dimesylate targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(tradeNames_list) LIKE "%lisdexamfetamine dimesylate%" OR LOWER(syns_list) LIKE "%lisdexamfetamine dimesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_419192', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419225', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419236', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419247', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419269', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419280', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419291', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419313', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419324', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419335', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419346', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419368', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419379', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419390', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419401', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419412', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419423', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419434', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419445', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419456', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419467', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419489', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419500', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419511', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419522', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419533', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419555', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419566', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419577', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419588', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419599', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419610', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419621', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419632', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419643', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419654', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419665', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419676', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419687', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419698', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419709', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419720', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419731', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419742', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419753', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419764', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419775', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419786', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419797', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419808', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419819', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419841', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419852', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419863', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419874', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419885', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419896', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419918', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419929', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419940', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419951', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419962', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419973', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419984', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419995', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420006', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420017', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420028', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420039', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420050', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420061', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420072', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420083', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420094', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420105', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420116', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420127', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420138', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420149', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420160', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420171', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420182', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420193', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420204', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420215', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_420226', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419830', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419478', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419302', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419214', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419170', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419148', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419137', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419907', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419544', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419357', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419258', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419203', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419181', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419159', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1057 | Q34 | What are the names of the genes that are targeted by the drug Fluorouracil in the treatment of actinic keratosis? | In the context of actinic keratosis, the drug Fluorouracil targets the gene thymidylate synthetase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%actinic keratosis%" OR LOWER(efo_term) LIKE "%actinic keratosis%") AND (LOWER(drugName) LIKE "%fluorouracil%" OR LOWER(tradeNames_list) LIKE "%fluorouracil%" OR LOWER(syns_list) LIKE "%fluorouracil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919465', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.510 | Q34 | What are the names of the genes that are targeted by the drug Amantadine Hydrochloride in the treatment of Parkinsonism? | In the context of Parkinsonism, the drug Amantadine Hydrochloride targets the gene glutamate ionotropic receptor NMDA type subunit 1, glutamate ionotropic receptor NMDA type subunit 2A, glutamate ionotropic receptor NMDA type subunit 2B, glutamate ionotropic receptor NMDA type subunit 2D, glutamate ionotropic receptor NMDA type subunit 3B, glutamate ionotropic receptor NMDA type subunit 2C and glutamate ionotropic receptor NMDA type subunit 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinsonism%" OR LOWER(efo_term) LIKE "%parkinsonism%") AND (LOWER(drugName) LIKE "%amantadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%amantadine hydrochloride%" OR LOWER(syns_list) LIKE "%amantadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_441088', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441130', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441144', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441158', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441186', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441200', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441214', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441242', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441256', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441270', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441284', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441312', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441326', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441340', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441354', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441368', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441382', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441396', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441410', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441424', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441438', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441466', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441480', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441494', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441508', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441522', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441550', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441564', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441578', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441592', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441606', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441620', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441634', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441648', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441662', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441676', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441690', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441704', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441718', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441732', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441746', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441760', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441774', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441788', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441802', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441816', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441830', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441844', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441858', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441872', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441886', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441914', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441928', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441942', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441956', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441970', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441984', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442012', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442026', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442040', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442054', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442068', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442082', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442096', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442110', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442124', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442138', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442152', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442166', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442180', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442194', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442208', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442222', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442236', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442250', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442264', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442278', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442292', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442306', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442320', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442334', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442348', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442362', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442376', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442390', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_442404', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441900', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441452', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441228', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441116', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441060', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441032', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441018', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441998', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441536', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441298', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441172', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441102', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441074', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_441046', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': "['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']", 'syns_list': "['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinsonian Disorders', 'efo_term': 'Parkinsonism', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.814 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828371', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828473', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828507', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828541', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828439', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828303', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828235', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828201', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828575', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828405', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828337', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828269', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.746 | Q34 | What are the names of the genes that are targeted by the drug Buprenorphine in the treatment of opioid dependence? | In the context of opioid dependence, the drug Buprenorphine targets the gene opioid receptor mu 1 and opioid receptor kappa 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%opioid dependence%" OR LOWER(efo_term) LIKE "%opioid dependence%") AND (LOWER(drugName) LIKE "%buprenorphine%" OR LOWER(tradeNames_list) LIKE "%buprenorphine%" OR LOWER(syns_list) LIKE "%buprenorphine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_764505', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764421', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765541', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764337', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764393', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764729', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764449', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765513', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764533', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764561', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765149', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765261', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764169', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764673', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765317', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764757', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764085', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764281', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764813', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764869', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764897', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764953', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764981', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765009', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765037', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765065', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765121', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766269', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765177', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765205', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765233', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766493', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764645', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766465', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764057', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765429', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764113', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764477', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764785', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765485', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764365', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765597', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765373', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764309', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765625', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765653', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765681', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765709', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765737', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765765', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765793', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765849', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765877', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765905', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765933', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765961', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765989', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766045', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766073', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766101', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766129', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766157', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766185', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766213', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766241', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765401', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766297', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766325', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766353', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766381', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766409', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766437', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765569', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764197', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766521', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_766549', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765289', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764701', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765821', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764925', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764589', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764253', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764141', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765457', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764841', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766017', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_765093', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764617', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_765345', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1'}, {'UUID': 'DrugTargetsIndication121923_text_764225', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'syns_list': "['ALKS-5461 COMPONENT BUPRENORPHINE', 'Brixadi', 'BuprenorphinBuprenorphine', 'Suboxone']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766553', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766555', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766557', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766559', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766561', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766563', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766565', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766567', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766569', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766571', 'drugName': 'Buprenorphine Hydrochloride', 'tradeNames_list': "['Belbuca', 'Buprenex', 'Buprenorphine hydrochloride', 'Espranor', 'GabupNatzon', 'Prefibin', 'Probuphine', 'Subutex']", 'syns_list': "['Anorfin', 'Buprederm', 'Buprenorphine hcl', 'Buprenorphine hydrochlorideBuprenorphine hydrochloride ciii', 'Buprex', 'CL 112,302', 'CL-112302Finibron', 'Lepetan', 'M-6029', 'NIH 8805', 'NIH-8805', 'NopanRX 6029-M HCL', 'RX-6029-M HCL', 'SCH-028444', 'UM 952', 'UM-952Vetergesic']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1972 | Q34 | What are the names of the genes that are targeted by the drug Topotecan Hydrochloride in the treatment of ovarian neoplasm? | In the context of ovarian neoplasm, the drug Topotecan Hydrochloride targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ovarian neoplasm%" OR LOWER(efo_term) LIKE "%ovarian neoplasm%") AND (LOWER(drugName) LIKE "%topotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%topotecan hydrochloride%" OR LOWER(syns_list) LIKE "%topotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193649', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193575', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193574', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193646', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193647', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193577', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.794 | Q34 | What are the names of the genes that are targeted by the drug Calcifediol in the treatment of chronic kidney disease? | In the context of chronic kidney disease, the drug Calcifediol targets the gene vitamin D receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic kidney disease%" OR LOWER(efo_term) LIKE "%chronic kidney disease%") AND (LOWER(drugName) LIKE "%calcifediol%" OR LOWER(tradeNames_list) LIKE "%calcifediol%" OR LOWER(syns_list) LIKE "%calcifediol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823426', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823450', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823458', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823466', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823482', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823490', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823498', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823514', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823522', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823530', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823506', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823410', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823394', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823386', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823442', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823474', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823434', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823418', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823402', 'drugName': 'Calcifediol', 'tradeNames_list': "['Calderol', 'Rayaldee']", 'syns_list': "['CTAP101', 'Calcidiol', 'Calcifediol', 'Calcifediol hydrate', 'Ctap-101Didrogyl', 'Hidroferol', 'Rayaldy', 'U-32,070E', 'U-32070E']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Renal Insufficiency, Chronic', 'efo_term': 'chronic kidney disease', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.823 | Q34 | What are the names of the genes that are targeted by the drug Nepafenac in the treatment of eye inflammation? | In the context of eye inflammation, the drug Nepafenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye inflammation%" OR LOWER(efo_term) LIKE "%eye inflammation%") AND (LOWER(drugName) LIKE "%nepafenac%" OR LOWER(tradeNames_list) LIKE "%nepafenac%" OR LOWER(syns_list) LIKE "%nepafenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828611', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828626', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828631', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828636', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828621', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828601', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828591', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828586', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828641', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828616', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828606', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828596', 'drugName': 'Nepafenac', 'tradeNames_list': "['Ilevro', 'Nepafenac', 'Nevanac']", 'syns_list': "['AHR-9434', 'AL-6515', 'Nepafenac']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1750 | Q34 | What are the names of the genes that are targeted by the drug Esomeprazole Magnesium in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Esomeprazole Magnesium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_list) LIKE "%esomeprazole magnesium%" OR LOWER(syns_list) LIKE "%esomeprazole magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097877', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097865', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097901', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097889', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.313 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of hemolytic anemia? | In the context of hemolytic anemia, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemolytic anemia%" OR LOWER(efo_term) LIKE "%hemolytic anemia%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227769', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228624', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228909', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229194', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229764', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230049', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230334', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230904', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231189', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231474', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231759', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232329', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230619', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228339', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227199', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226629', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226344', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232044', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229479', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228054', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227484', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226914', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic', 'efo_term': 'hemolytic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1186 | Q34 | What are the names of the genes that are targeted by the drug Fedratinib Hydrochloride in the treatment of Myelofibrosis? | In the context of Myelofibrosis, the drug Fedratinib Hydrochloride targets the gene fms related receptor tyrosine kinase 3 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myelofibrosis%" OR LOWER(efo_term) LIKE "%myelofibrosis%") AND (LOWER(drugName) LIKE "%fedratinib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%fedratinib hydrochloride%" OR LOWER(syns_list) LIKE "%fedratinib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933946', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933949', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933950', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933951', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933953', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933954', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933955', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933957', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933958', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933959', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933960', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933948', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933944', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933942', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933941', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933956', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933952', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_933947', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933945', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_933943', 'drugName': 'Fedratinib Hydrochloride', 'tradeNames_list': "['Inrebic']", 'syns_list': "['Fedratinib hydrochloride', 'SAR302503A']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.408 | Q34 | What are the names of the genes that are targeted by the drug Prednisolone Acetate in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Prednisolone Acetate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%prednisolone acetate%" OR LOWER(tradeNames_list) LIKE "%prednisolone acetate%" OR LOWER(syns_list) LIKE "%prednisolone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243762', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243745', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243796', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243779', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.675 | Q34 | What are the names of the genes that are targeted by the drug Pemigatinib in the treatment of cancer? | In the context of cancer, the drug Pemigatinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3 and fibroblast growth factor receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%pemigatinib%" OR LOWER(tradeNames_list) LIKE "%pemigatinib%" OR LOWER(syns_list) LIKE "%pemigatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_706910', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706988', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706884', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707040', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707079', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706949', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706975', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707014', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706897', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707001', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707027', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706871', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707066', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706858', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706923', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706962', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707053', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706936', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706948', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706882', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706908', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706960', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706869', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707064', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706921', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706947', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706987', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707078', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707065', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706974', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706961', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706934', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707077', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707052', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707051', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707013', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706909', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707012', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707000', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706999', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706922', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707039', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707026', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707025', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706870', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706883', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706857', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706856', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706895', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706935', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707038', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_706896', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_706973', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_706986', 'drugName': 'Pemigatinib', 'tradeNames_list': "['Pemazyre']", 'syns_list': "['Fgfr inhibitor incb054828', 'INCB054828', 'Incb-054828', 'Incb054828Pemigatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1412 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of rosacea? | In the context of rosacea, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rosacea%" OR LOWER(efo_term) LIKE "%rosacea%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038226', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040851', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040026', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038151', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039276', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039126', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1040776', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039426', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1040101', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040176', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040251', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040701', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038076', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040626', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039501', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037851', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039876', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038751', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038451', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038301', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040326', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038901', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039801', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039351', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039951', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040401', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040551', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038601', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038526', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038676', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038001', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038826', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037926', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039651', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038976', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039051', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039726', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1041001', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1038376', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040926', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041076', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039201', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1040476', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039576', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037109', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037406', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037417', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037494', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037483', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037472', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037461', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037450', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037439', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037428', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037505', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037681', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1036889', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037395', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1036922', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037032', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037252', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036966', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037120', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037131', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037703', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037263', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037714', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037043', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037274', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037736', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037285', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037758', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037769', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1036933', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037054', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037296', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036977', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037780', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037307', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037065', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037747', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037318', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037329', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037725', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1036845', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036878', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1036944', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037076', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037692', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1037340', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037351', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037087', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037362', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1036867', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037373', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1036955', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037098', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037384', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037142', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037153', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'syns_list': "['Azudoxat', 'Clinofug', 'Diocimex', 'Doxicrisol', 'Doxycycline hyclateDoxycycline hydrochloride hemiethanolate hemihydrateDoxycycline hydrochloride hydrate', 'Doxycyclini hyclas', 'DoxyprexDuradoxal', 'Granudoxy', 'Mespafin', 'Monodoks', 'NSC-741421', 'RetensRonaxan', 'Spanor', 'Tetraclean', 'Tetradox', 'Unacil', 'VibraveineuseVibravenos', 'Zadorin']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rosacea', 'efo_term': 'rosacea', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.311 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of pemphigus vulgaris? | In the context of pemphigus vulgaris, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pemphigus vulgaris%" OR LOWER(efo_term) LIKE "%pemphigus vulgaris%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227767', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227197', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226627', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228052', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227482', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226912', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.228 | Q34 | What are the names of the genes that are targeted by the drug Betamethasone Dipropionate in the treatment of eye inflammation? | In the context of eye inflammation, the drug Betamethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye inflammation%" OR LOWER(efo_term) LIKE "%eye inflammation%") AND (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%betamethasone dipropionate%" OR LOWER(syns_list) LIKE "%betamethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220895', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220871', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220847', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220835', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220907', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220883', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220859', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_list': "['Alphatrex', 'Betamethasone dipropionate', 'Diprolene', 'Diprolene afDiprosone', 'Sernivo']", 'syns_list': "['Betamethasone (as dipropionate)', 'Betamethasone 17,21-dipropionateBetamethasone dipropionate', 'Diprospan', 'Maxivate', 'NSC-758415Rinderon dp', 'SCH 11460', 'SCH-11460']", 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1684 | Q34 | What are the names of the genes that are targeted by the drug Dapagliflozin Propylene Glycol in the treatment of heart failure? | In the context of heart failure, the drug Dapagliflozin Propylene Glycol targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%dapagliflozin propylene glycol%" OR LOWER(tradeNames_list) LIKE "%dapagliflozin propylene glycol%" OR LOWER(syns_list) LIKE "%dapagliflozin propylene glycol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096259', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096268', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096271', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096274', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096280', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096283', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096286', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096292', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096295', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096298', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096301', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096307', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096310', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096313', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096316', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096319', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096322', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096325', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096328', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096331', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096334', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096340', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096343', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096346', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096349', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096352', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096358', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096337', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096289', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096265', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096253', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096247', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096244', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096355', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096304', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096277', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096262', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096256', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096250', 'drugName': 'Dapagliflozin Propylene Glycol', 'tradeNames_list': "['Farxiga']", 'syns_list': "['BMS-512148-05', 'Dapagliflozin', 'Dapagliflozin propanediolDapagliflozin propylene glycol']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.913 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of rheumatic disease? | In the context of rheumatic disease, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatic disease%" OR LOWER(efo_term) LIKE "%rheumatic disease%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838543', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838666', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838707', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838748', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838830', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838871', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838912', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838994', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839035', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839076', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839117', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839199', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839240', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839281', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839322', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839363', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839404', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839445', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839486', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839527', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839568', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839650', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839691', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839609', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838953', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838625', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838379', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838338', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838461', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839158', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838789', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838584', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838502', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838420', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1515 | Q34 | What are the names of the genes that are targeted by the drug Azilsartan Kamedoxomil in the treatment of hypertension? | In the context of hypertension, the drug Azilsartan Kamedoxomil targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%azilsartan kamedoxomil%" OR LOWER(tradeNames_list) LIKE "%azilsartan kamedoxomil%" OR LOWER(syns_list) LIKE "%azilsartan kamedoxomil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072675', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072667', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072665', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072671', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072673', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072669', 'drugName': 'Azilsartan Kamedoxomil', 'tradeNames_list': "['Edarbi']", 'syns_list': "['Azilsartan kamedoxomil', 'Azilsartan medoxomil potassium', 'TAK-491']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.798 | Q34 | What are the names of the genes that are targeted by the drug Calcipotriene in the treatment of psoriasis vulgaris? | In the context of psoriasis vulgaris, the drug Calcipotriene targets the gene vitamin D receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis vulgaris%" OR LOWER(efo_term) LIKE "%psoriasis vulgaris%") AND (LOWER(drugName) LIKE "%calcipotriene%" OR LOWER(tradeNames_list) LIKE "%calcipotriene%" OR LOWER(syns_list) LIKE "%calcipotriene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823602', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823638', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823650', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823662', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823686', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823698', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823710', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823722', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823626', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823578', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823554', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823542', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823674', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823614', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823590', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}, {'UUID': 'DrugTargetsIndication121923_text_823566', 'drugName': 'Calcipotriene', 'tradeNames_list': "['Calcipotriene', 'Dovobet', 'Dovonex', 'Enstilar', 'Sorilux', 'Xamiol']", 'syns_list': "['Calcipotriene', 'Calcipotriene hydrate', 'Calcipotriene monohydrateCalcipotriol', 'Calcipotriol anhydrous', 'Calcipotriol hydrateCalcipotriol monohydrate', 'Calciptriol', 'MC 903', 'MC-903', 'PRI-2201']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'VDR', 'approvedName': 'vitamin D receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.769 | Q34 | What are the names of the genes that are targeted by the drug Fentanyl in the treatment of migraine disorder? | In the context of migraine disorder, the drug Fentanyl targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%fentanyl%" OR LOWER(tradeNames_list) LIKE "%fentanyl%" OR LOWER(syns_list) LIKE "%fentanyl%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_785914', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786028', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786066', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786104', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786180', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786218', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786256', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786332', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786370', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786408', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786446', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786522', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786560', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786598', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786636', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786674', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786712', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786750', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786788', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786826', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786864', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786940', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786978', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787016', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787054', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787092', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787168', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787206', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787244', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787282', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787320', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787358', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787396', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787434', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787472', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787510', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787548', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787586', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787624', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787662', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787700', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787738', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787776', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787814', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787852', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787890', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787928', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787966', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788004', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788042', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788080', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788156', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788194', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788232', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788270', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788308', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788346', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788422', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788460', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788498', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788536', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788574', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788612', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788650', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788688', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788726', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788764', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788802', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788840', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788878', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788916', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788954', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788992', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789030', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789068', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789106', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789144', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789182', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789220', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789258', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789296', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_789334', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788118', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786902', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786294', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785990', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785838', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785762', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785724', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_788384', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_787130', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786484', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_786142', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785952', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785876', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_785800', 'drugName': 'Fentanyl', 'tradeNames_list': "['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']", 'syns_list': "['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.150 | Q34 | What are the names of the genes that are targeted by the drug Ciclesonide in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Ciclesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%ciclesonide%" OR LOWER(tradeNames_list) LIKE "%ciclesonide%" OR LOWER(syns_list) LIKE "%ciclesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217451', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217441', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217471', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217461', 'drugName': 'Ciclesonide', 'tradeNames_list': "['Alvesco', 'Alvesco 160', 'Alvesco 80', 'Omnaris', 'Zetonna']", 'syns_list': "['BI54903', 'Ciclesonide', 'RPR-251526', 'RPR251526']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.603 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of Lennox-Gastaut syndrome? | In the context of Lennox-Gastaut syndrome, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lennox-gastaut syndrome%" OR LOWER(efo_term) LIKE "%lennox-gastaut syndrome%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653157', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653250', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653281', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653312', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653374', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653405', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653436', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653498', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653529', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653560', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653591', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653653', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653684', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653715', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653746', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653777', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653808', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653839', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653870', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653901', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653932', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653994', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654025', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654056', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654087', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654118', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654180', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654211', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654242', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654273', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654304', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654335', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654366', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654397', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654428', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654459', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654490', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654521', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654552', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654583', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654614', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654645', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654676', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654707', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654738', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654769', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654800', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654831', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654862', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654893', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654924', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654986', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655017', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655048', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655079', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655110', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655141', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655203', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655234', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655265', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655296', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655327', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655358', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655389', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655420', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655451', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655482', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655513', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655544', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655575', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655606', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655637', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655668', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655699', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655730', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655761', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655792', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655823', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655854', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655885', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655916', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655947', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655978', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656009', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656040', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656071', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_654955', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_653963', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653467', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653219', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653095', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653033', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653002', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_655172', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654149', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_653622', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653343', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653188', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653126', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653064', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1931 | Q34 | What are the names of the genes that are targeted by the drug Azacitidine in the treatment of neoplasm? | In the context of neoplasm, the drug Azacitidine targets the gene DNA methyltransferase 1 and DNA methyltransferase 3 alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%azacitidine%" OR LOWER(tradeNames_list) LIKE "%azacitidine%" OR LOWER(syns_list) LIKE "%azacitidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191917', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191916', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191978', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192040', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192103', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191979', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192102', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192041', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191891', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192009', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191885', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191964', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191957', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191962', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192025', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191889', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192026', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192075', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191902', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191963', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192079', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192011', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'lymphoid neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191893', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191955', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192087', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191901', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191887', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'lymphoid neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192019', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191953', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191907', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192077', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192015', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192017', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192013', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192081', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191949', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'lymphoid neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192020', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192024', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192071', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192030', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192031', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191969', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191896', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192073', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'lymphoid neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191906', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191900', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192093', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192086', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192082', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191968', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191951', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191958', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192088', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192092', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191895', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191947', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191932', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191997', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191935', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191873', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192054', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192056', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191992', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191868', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191994', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191930', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191870', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192059', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1191921', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191983', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192107', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192045', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'syns_list': "['5-azacitidine', 'Azacitidine', 'Ladakamycin', 'NSC-102816', 'U-18,496U-18496', 'Vidaza']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.885 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of rheumatic disease? | In the context of rheumatic disease, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatic disease%" OR LOWER(efo_term) LIKE "%rheumatic disease%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_837131', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837221', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837251', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837281', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837341', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837371', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837401', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837461', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837491', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837521', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837551', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837611', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837641', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837671', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837701', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837731', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837761', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837791', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837821', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837851', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837881', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837941', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837971', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838001', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838031', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837911', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837191', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837071', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837011', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836981', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837431', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837581', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837311', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837161', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837101', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837041', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rheumatic Diseases', 'efo_term': 'rheumatic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1207 | Q34 | What are the names of the genes that are targeted by the drug Albuterol in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Albuterol targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%albuterol%" OR LOWER(tradeNames_list) LIKE "%albuterol%" OR LOWER(syns_list) LIKE "%albuterol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936247', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936274', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936283', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936292', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936310', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936319', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936328', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936346', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936355', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936364', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936373', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936391', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936400', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936409', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936418', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936427', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936436', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936445', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936454', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936463', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936472', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936490', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936499', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936508', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936517', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936526', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936544', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936553', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936562', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936571', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936580', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936589', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936618', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936647', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936676', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936705', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936734', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936763', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936792', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936821', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936850', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936879', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936908', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936937', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936966', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936995', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936481', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936337', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936265', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936229', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936211', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936202', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936535', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936382', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936301', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936256', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936238', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936220', 'drugName': 'Albuterol Sulfate', 'tradeNames_list': "['Accuneb', 'Albuterol sulfate', 'Proair', 'Proair digihaler', 'Proair hfaProair respiclick', 'Proventil', 'Proventil-hfa', 'Ventolin', 'Ventolin hfaVentolin rotacaps', 'Volmax', 'Vospire er']", 'syns_list': "['Albuterol sulfate', 'Albuterol sulphate', 'Buventol', 'Ecovent', 'HexotonalLoftan', 'NSC-289928', 'R03AC02', 'R03CC02', 'SCH 13949W SULFATESCH-13949W SULFATE', 'Salamol', 'Salbumol', 'Salbutamol (as sulfate)Salbutamol sulfate', 'Salbutamol sulphate', 'Salbutamoli sulfasSch 13949w sulphate', 'Sch-13949w sulphate', 'Sulbutamol (as sulphate)Sultanol', 'Torpex', 'Venetlin', 'Ventilastin', 'Vospire']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.808 | Q34 | What are the names of the genes that are targeted by the drug Pitolisant Hydrochloride in the treatment of narcolepsy-cataplexy syndrome? | In the context of narcolepsy-cataplexy syndrome, the drug Pitolisant Hydrochloride targets the gene histamine receptor H3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy-cataplexy syndrome%" OR LOWER(efo_term) LIKE "%narcolepsy-cataplexy syndrome%") AND (LOWER(drugName) LIKE "%pitolisant hydrochloride%" OR LOWER(tradeNames_list) LIKE "%pitolisant hydrochloride%" OR LOWER(syns_list) LIKE "%pitolisant hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828134', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828140', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828142', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828138', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828126', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828124', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828130', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828136', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828132', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}, {'UUID': 'DrugTargetsIndication121923_text_828128', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_list': "['Wakix']", 'syns_list': "['Ciproxidine', 'Pitolisant hydrochloride']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'HRH3', 'approvedName': 'histamine receptor H3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.579 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of frozen shoulder? | In the context of frozen shoulder, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%frozen shoulder%" OR LOWER(efo_term) LIKE "%frozen shoulder%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638369', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638714', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638829', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638944', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639174', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639289', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639404', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639634', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639749', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639864', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639979', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640209', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640324', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640439', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640554', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640669', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640784', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640899', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641014', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641129', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641244', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641474', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641589', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641704', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641819', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641934', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642164', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642279', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642394', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642509', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642624', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642739', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642854', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642969', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643084', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643199', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643314', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643429', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643544', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643659', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643774', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643889', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644004', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644119', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644234', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644349', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644464', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644579', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641359', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639519', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638599', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638139', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637909', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637794', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642049', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640094', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639059', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638484', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638254', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638024', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.561 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of Pruritus? | In the context of Pruritus, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pruritus%" OR LOWER(efo_term) LIKE "%pruritus%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_640880', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640995', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639500', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_641800', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639040', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_642490', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639960', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637890', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_643755', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644215', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_638580', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_643295', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_642605', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642145', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_644100', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_638810', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640765', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641225', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_642375', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_644445', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_640190', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640650', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642950', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_641110', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642720', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643180', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642260', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642835', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637775', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638925', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638005', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639270', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638235', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639730', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638465', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638695', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641685', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639385', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_641455', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_640535', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_638350', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641570', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_643065', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642030', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639615', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_643985', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_639845', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_641915', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640075', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638120', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_643870', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644330', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644560', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_640420', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_643525', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_641340', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639155', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640305', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_643410', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643640', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637173', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636893', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636913', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636953', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637033', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637193', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637473', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637533', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637213', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637553', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637053', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637233', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637593', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637253', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637633', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637653', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636973', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637073', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637273', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637673', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637613', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637293', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637093', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637313', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637333', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637573', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636933', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636993', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637113', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637353', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637513', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637373', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637133', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637393', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637413', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637013', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637153', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637433', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637453', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637493', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pruritus', 'efo_term': 'Pruritus', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1351 | Q34 | What are the names of the genes that are targeted by the drug Tranexamic Acid in the treatment of hemorrhage? | In the context of hemorrhage, the drug Tranexamic Acid targets the gene plasminogen. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhage%" OR LOWER(efo_term) LIKE "%hemorrhage%") AND (LOWER(drugName) LIKE "%tranexamic acid%" OR LOWER(tradeNames_list) LIKE "%tranexamic acid%" OR LOWER(syns_list) LIKE "%tranexamic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993618', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993676', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993560', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993444', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993328', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993502', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993386', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993734', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993284', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993600', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993426', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993658', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993342', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993542', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993716', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993458', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993574', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993310', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993632', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993368', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993400', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993690', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993484', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993516', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993334', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993395', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993566', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993511', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993569', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993337', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993276', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993450', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993453', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993627', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993279', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993682', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993685', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993392', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993508', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993624', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Subarachnoid Hemorrhage', 'efo_term': 'subarachnoid hemorrhage', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1627 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of Ischemic stroke? | Dabigatran has not been approved by the FDA as a treatment for Ischemic stroke, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ischemic stroke%" OR LOWER(efo_term) LIKE "%ischemic stroke%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093460', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093493', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093504', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093515', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093537', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093548', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093559', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093581', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093592', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093603', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093614', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093636', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093647', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093658', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093669', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093680', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093691', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093702', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093713', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093724', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093735', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093757', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093768', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093779', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093790', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093801', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093823', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093834', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093845', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093856', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093867', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093878', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093889', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093900', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093911', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093922', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093933', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093944', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093955', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093966', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093977', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093988', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093999', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094010', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094021', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093746', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093570', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093482', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093438', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093416', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093405', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093812', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093625', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093526', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093471', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093449', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093427', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ischemic Stroke', 'efo_term': 'Ischemic stroke', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1661 | Q34 | What are the names of the genes that are targeted by the drug Spironolactone in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Spironolactone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%spironolactone%" OR LOWER(tradeNames_list) LIKE "%spironolactone%" OR LOWER(syns_list) LIKE "%spironolactone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094351', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094541', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094389', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094579', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094655', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094427', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094503', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094617', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094465', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094418', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094457', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094343', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094419', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094494', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094646', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094533', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094570', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094609', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094532', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094380', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094608', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094381', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094342', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094456', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094571', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094647', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094495', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1705 | Q34 | What are the names of the genes that are targeted by the drug Histrelin Acetate in the treatment of prostate cancer? | In the context of prostate cancer, the drug Histrelin Acetate targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%histrelin acetate%" OR LOWER(tradeNames_list) LIKE "%histrelin acetate%" OR LOWER(syns_list) LIKE "%histrelin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097121', 'drugName': 'Histrelin Acetate', 'tradeNames_list': "['Supprelin', 'Supprelin la', 'Vantas']", 'syns_list': "['Histrelin acetate']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.922 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of tendinitis? | In the context of tendinitis, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tendinitis%" OR LOWER(efo_term) LIKE "%tendinitis%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838552', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838675', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838716', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838757', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838839', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838880', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838921', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839003', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839044', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839085', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839126', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839208', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839249', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839290', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839331', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839372', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839413', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839454', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839495', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839536', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839577', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839659', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839700', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839618', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838962', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838634', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838388', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838347', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838470', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839167', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838798', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838593', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838511', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838429', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.288 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Chorioretinitis? | In the context of Chorioretinitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chorioretinitis%" OR LOWER(efo_term) LIKE "%chorioretinitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227743', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228598', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228883', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229168', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229738', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230023', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230308', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230878', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231163', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231448', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231733', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232303', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230593', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228313', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227173', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226603', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226318', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232018', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229453', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228028', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227458', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226888', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1800 | Q34 | What are the names of the genes that are targeted by the drug Famotidine in the treatment of Chest pain? | In the context of Chest pain, the drug Famotidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chest pain%" OR LOWER(efo_term) LIKE "%chest pain%") AND (LOWER(drugName) LIKE "%famotidine%" OR LOWER(tradeNames_list) LIKE "%famotidine%" OR LOWER(syns_list) LIKE "%famotidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100334', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'syns_list': "['Amfamox', 'Fadul', 'Famodil', 'Famosan', 'Famotidine', 'Famoxal', 'GanorGastridin', 'Gastropen', 'L 643341', 'Lecedil', 'MK-208', 'Motiax', 'MucloxNSC-757810', 'Pepcidac', 'Pepdine', 'Pepdul', 'YM-11170']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chest Pain', 'efo_term': 'Chest pain', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1724 | Q34 | What are the names of the genes that are targeted by the drug Eliglustat Tartrate in the treatment of Gaucher disease? | In the context of Gaucher disease, the drug Eliglustat Tartrate targets the gene UDP-glucose ceramide glucosyltransferase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gaucher disease%" OR LOWER(efo_term) LIKE "%gaucher disease%") AND (LOWER(drugName) LIKE "%eliglustat tartrate%" OR LOWER(tradeNames_list) LIKE "%eliglustat tartrate%" OR LOWER(syns_list) LIKE "%eliglustat tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097559', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1097561', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1097557', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1097555', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1097554', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1097560', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1097558', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1097556', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'syns_list': "['Eliglustat hemitartrate', 'Eliglustat tartrate', 'GENZ 112638GENZ-112638']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1406 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of malaria? | In the context of malaria, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%malaria%" OR LOWER(efo_term) LIKE "%malaria%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038220', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038445', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038520', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038595', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038745', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038820', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038895', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039045', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039120', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039195', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039270', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039420', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039495', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039570', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039645', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039720', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039795', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039870', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039945', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040020', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040095', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040245', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040320', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040395', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040470', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040545', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040695', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040770', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040845', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040920', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040995', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041070', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040170', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038970', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038370', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038070', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037920', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037845', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040620', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039345', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038670', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038295', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038145', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037995', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Malaria', 'efo_term': 'malaria', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1623 | Q34 | What are the names of the genes that are targeted by the drug Argatroban in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Argatroban targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%argatroban%" OR LOWER(tradeNames_list) LIKE "%argatroban%" OR LOWER(syns_list) LIKE "%argatroban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093395', 'drugName': 'Argatroban', 'tradeNames_list': "['Acova', 'Argatroban', 'Argatroban in dextroseArgatroban in sodium chloride']", 'syns_list': "['Argatroban', 'Argatroban anhydrous', 'Argatroban hydrateArgatroban monohydrate', 'Argipidine', 'DK-7419', 'GN-1600', 'GN1600MCI-9038', 'MD-805']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093401', 'drugName': 'Argatroban', 'tradeNames_list': "['Acova', 'Argatroban', 'Argatroban in dextroseArgatroban in sodium chloride']", 'syns_list': "['Argatroban', 'Argatroban anhydrous', 'Argatroban hydrateArgatroban monohydrate', 'Argipidine', 'DK-7419', 'GN-1600', 'GN1600MCI-9038', 'MD-805']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1573 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of clear cell renal carcinoma? | In the context of clear cell renal carcinoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%clear cell renal carcinoma%" OR LOWER(efo_term) LIKE "%clear cell renal carcinoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085631', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086036', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086171', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086306', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086576', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086711', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086846', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087116', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087251', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087386', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087521', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087791', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087926', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088061', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088196', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088331', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088466', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088601', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088736', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088871', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089006', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089276', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089411', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089546', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089681', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089816', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090086', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090221', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090356', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090491', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090626', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089141', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086981', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085901', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085361', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085091', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084956', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089951', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087656', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086441', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085766', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085496', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085226', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1373 | Q34 | What are the names of the genes that are targeted by the drug Teriparatide in the treatment of osteoporosis? | In the context of osteoporosis, the drug Teriparatide targets the gene parathyroid hormone 1 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoporosis%" OR LOWER(efo_term) LIKE "%osteoporosis%") AND (LOWER(drugName) LIKE "%teriparatide%" OR LOWER(tradeNames_list) LIKE "%teriparatide%" OR LOWER(syns_list) LIKE "%teriparatide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025284', 'drugName': 'Teriparatide', 'tradeNames_list': "['Bonsity', 'Forsteo', 'Forteo']", 'syns_list': "['(1-34)-human parathyroid hormone', '1-34-human pthHuman parathyroid hormone 1-34', 'LY 333334', 'LY-333334', 'LY333334Pth (1-34)', 'Teriparatide', 'Teriparatide rdnaTeriparatide recombinant human', 'ZT-034']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025271', 'drugName': 'Teriparatide', 'tradeNames_list': "['Bonsity', 'Forsteo', 'Forteo']", 'syns_list': "['(1-34)-human parathyroid hormone', '1-34-human pthHuman parathyroid hormone 1-34', 'LY 333334', 'LY-333334', 'LY333334Pth (1-34)', 'Teriparatide', 'Teriparatide rdnaTeriparatide recombinant human', 'ZT-034']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025268', 'drugName': 'Teriparatide', 'tradeNames_list': "['Bonsity', 'Forsteo', 'Forteo']", 'syns_list': "['(1-34)-human parathyroid hormone', '1-34-human pthHuman parathyroid hormone 1-34', 'LY 333334', 'LY-333334', 'LY333334Pth (1-34)', 'Teriparatide', 'Teriparatide rdnaTeriparatide recombinant human', 'ZT-034']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025281', 'drugName': 'Teriparatide', 'tradeNames_list': "['Bonsity', 'Forsteo', 'Forteo']", 'syns_list': "['(1-34)-human parathyroid hormone', '1-34-human pthHuman parathyroid hormone 1-34', 'LY 333334', 'LY-333334', 'LY333334Pth (1-34)', 'Teriparatide', 'Teriparatide rdnaTeriparatide recombinant human', 'ZT-034']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1217 | Q34 | What are the names of the genes that are targeted by the drug Olodaterol Hydrochloride in the treatment of emphysema? | In the context of emphysema, the drug Olodaterol Hydrochloride targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%emphysema%" OR LOWER(efo_term) LIKE "%emphysema%") AND (LOWER(drugName) LIKE "%olodaterol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%olodaterol hydrochloride%" OR LOWER(syns_list) LIKE "%olodaterol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937111', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937120', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937123', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937126', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937132', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937117', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937105', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937099', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937096', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937129', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937114', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937108', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_937102', 'drugName': 'Olodaterol Hydrochloride', 'tradeNames_list': "['Striverdi respimat']", 'syns_list': "['BI 1744 CL', 'BI-1744 CL', 'BI-1744-CL', 'Olodaterol hydrochloride']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.780 | Q34 | What are the names of the genes that are targeted by the drug Niraparib in the treatment of neoplasm? | In the context of neoplasm, the drug Niraparib targets the gene poly(ADP-ribose) polymerase 2 and poly(ADP-ribose) polymerase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%niraparib%" OR LOWER(tradeNames_list) LIKE "%niraparib%" OR LOWER(syns_list) LIKE "%niraparib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823338', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793694', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793375', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823352', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823358', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793614', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793695', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793415', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823348', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823340', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793455', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823378', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823372', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823374', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823350', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823370', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823342', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793534', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793654', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823343', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823334', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793775', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823363', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793494', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823371', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793414', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823364', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823367', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823368', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793655', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793574', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793334', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793734', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823347', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823380', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823376', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823366', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793374', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823354', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793454', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793615', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793535', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823360', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823356', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793335', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793495', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823362', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793575', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823339', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823379', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823344', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823336', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793774', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793735', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823351', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823346', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823359', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823335', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823355', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823375', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793728', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793444', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793573', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793328', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793452', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793609', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793731', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793451', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793651', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793652', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793608', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793606', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793611', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793329', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793612', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793613', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793364', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793331', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793653', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793688', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793644', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793366', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793369', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793684', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793333', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793449', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793371', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793686', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793372', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793373', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_793646', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793689', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793691', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793693', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793733', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793692', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793724', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793726', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793732', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_793729', 'drugName': 'Niraparib', 'tradeNames_list': "['Zejula']", 'syns_list': "['JNJ-64091742', 'MK-4827', 'MK4827', 'Niraparib', 'ZL-2306']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1347 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of Tendinopathy? | In the context of Tendinopathy, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tendinopathy%" OR LOWER(efo_term) LIKE "%tendinopathy%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993231', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993157', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993083', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993046', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993268', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993194', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993120', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'Tendinopathy', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.618 | Q34 | What are the names of the genes that are targeted by the drug Cabozantinib in the treatment of neoplasm? | In the context of neoplasm, the drug Cabozantinib targets the gene kinase insert domain receptor and MET proto-oncogene, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%cabozantinib%" OR LOWER(tradeNames_list) LIKE "%cabozantinib%" OR LOWER(syns_list) LIKE "%cabozantinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_669860', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669581', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669788', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669742', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669837', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670248', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669676', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669696', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669951', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669627', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670018', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669811', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669814', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670182', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670159', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670202', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670204', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670250', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669606', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669857', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670251', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669882', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669768', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669699', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669974', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669560', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669629', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670066', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669584', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670021', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670041', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670089', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669745', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670090', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670110', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670228', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669652', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670181', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670179', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670227', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669836', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670225', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670205', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670294', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669859', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669673', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669675', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670274', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669607', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670273', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670271', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669653', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669903', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669883', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669928', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669698', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669926', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669997', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669949', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669972', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669952', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669995', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669583', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669719', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669721', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670136', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669630', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669791', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669790', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670064', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670020', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670044', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670043', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670135', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669744', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670087', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670067', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670133', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669813', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670113', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670112', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670296', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669834', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669765', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669767', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670317', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670297', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670156', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669998', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669929', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669905', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669880', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669558', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669906', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669975', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669561', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670158', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669604', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669722', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669650', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1646 | Q34 | What are the names of the genes that are targeted by the drug Vardenafil Hydrochloride in the treatment of erectile dysfunction? | In the context of erectile dysfunction, the drug Vardenafil Hydrochloride targets the gene phosphodiesterase 5A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%erectile dysfunction%" OR LOWER(efo_term) LIKE "%erectile dysfunction%") AND (LOWER(drugName) LIKE "%vardenafil hydrochloride%" OR LOWER(tradeNames_list) LIKE "%vardenafil hydrochloride%" OR LOWER(syns_list) LIKE "%vardenafil hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094112', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094115', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094114', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094110', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094107', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094108', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094113', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094111', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}, {'UUID': 'DrugTargetsIndication121923_text_1094109', 'drugName': 'Vardenafil Hydrochloride', 'tradeNames_list': "['Levitra', 'Staxyn', 'Vardenafil hydrochloride']", 'syns_list': "['BAY 38-9456', 'BAY-38-9456', 'Nuviva', 'Vardenafil hclVardenafil hydrochloride', 'Vardenafil hydrochloride anhydrousVardenafil hydrochloride hydrate', 'Vardenafil hydrochloride trihydrateVardenafil monohydrochloride']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erectile Dysfunction', 'efo_term': 'erectile dysfunction', 'approvedSymbol': 'PDE5A', 'approvedName': 'phosphodiesterase 5A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1402 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of infection? | In the context of infection, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%infection%" OR LOWER(efo_term) LIKE "%infection%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1039493', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038369', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038819', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039191', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039644', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039941', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040019', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038216', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038443', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038591', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038966', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039194', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037844', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039643', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039568', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039718', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039719', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040018', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039943', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040093', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040094', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038069', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038219', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038291', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038519', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038444', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038666', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039119', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038891', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039041', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039043', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039268', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037841', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039341', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037916', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039866', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037991', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039641', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039569', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039794', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039716', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039793', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039791', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040241', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039869', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040016', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039944', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040169', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040091', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040168', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040166', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038066', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038143', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038141', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038366', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038218', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038294', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038743', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038441', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038518', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038516', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038741', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038593', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038669', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038668', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039418', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038818', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038894', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038893', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039118', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038969', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039116', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039044', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039416', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039193', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039266', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037843', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1039344', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039269', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039343', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037918', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040243', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039491', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039494', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1037993', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040316', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040244', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039419', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038744', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038368', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038144', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038068', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037994', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038293', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038594', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038968', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039566', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039868', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bacterial Infections', 'efo_term': 'bacterial disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038816', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1037919', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anthrax', 'efo_term': 'anthrax infection', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1975 | Q34 | What are the names of the genes that are targeted by the drug Topotecan Hydrochloride in the treatment of malignant epithelial tumor of ovary? | In the context of malignant epithelial tumor of ovary, the drug Topotecan Hydrochloride targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%malignant epithelial tumor of ovary%" OR LOWER(efo_term) LIKE "%malignant epithelial tumor of ovary%") AND (LOWER(drugName) LIKE "%topotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%topotecan hydrochloride%" OR LOWER(syns_list) LIKE "%topotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193579', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'malignant epithelial tumor of ovary', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193651', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'malignant epithelial tumor of ovary', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1141 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of amyotrophic lateral sclerosis? | Trametinib has not been approved by the FDA as a treatment for amyotrophic lateral sclerosis, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%amyotrophic lateral sclerosis%" OR LOWER(efo_term) LIKE "%amyotrophic lateral sclerosis%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928689', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928809', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928849', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928889', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928969', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929009', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929049', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929129', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929169', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929209', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929249', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929329', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929369', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929409', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929449', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929489', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929529', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929569', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929609', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929649', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929689', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929769', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929809', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929849', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929889', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929929', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930009', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930049', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930089', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930129', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930169', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930209', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930249', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930289', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930329', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930369', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930409', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930449', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930489', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930529', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930569', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930609', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930649', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930689', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930729', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930769', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930809', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930849', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930889', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930929', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930969', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931049', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931089', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931129', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931169', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931209', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931249', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931329', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931369', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931409', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931449', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931489', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931529', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931569', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931609', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931649', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931689', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931729', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931769', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931809', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931849', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931889', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931929', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931969', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932009', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932049', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932089', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932129', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932169', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932209', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932249', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932289', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932329', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932369', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932409', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932449', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931009', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929729', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929089', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928769', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928609', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928529', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928489', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931289', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929969', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929289', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928929', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928729', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928649', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928569', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Amyotrophic Lateral Sclerosis', 'efo_term': 'amyotrophic lateral sclerosis', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1567 | Q34 | What are the names of the genes that are targeted by the drug Sirolimus in the treatment of immune system disease? | In the context of immune system disease, the drug Sirolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%sirolimus%" OR LOWER(tradeNames_list) LIKE "%sirolimus%" OR LOWER(syns_list) LIKE "%sirolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084563', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084428', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084833', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084698', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1231 | Q34 | What are the names of the genes that are targeted by the drug Metoprolol Succinate in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Metoprolol Succinate targets the gene adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%metoprolol succinate%" OR LOWER(tradeNames_list) LIKE "%metoprolol succinate%" OR LOWER(syns_list) LIKE "%metoprolol succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937655', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937677', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937633', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937611', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937600', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937666', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937644', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937622', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.497 | Q34 | What are the names of the genes that are targeted by the drug Tapentadol Hydrochloride in the treatment of neuropathic pain? | In the context of neuropathic pain, the drug Tapentadol Hydrochloride targets the gene solute carrier family 6 member 2 and opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neuropathic pain%" OR LOWER(efo_term) LIKE "%neuropathic pain%") AND (LOWER(drugName) LIKE "%tapentadol hydrochloride%" OR LOWER(tradeNames_list) LIKE "%tapentadol hydrochloride%" OR LOWER(syns_list) LIKE "%tapentadol hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434272', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434287', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434292', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434297', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434307', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434312', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434317', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434327', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434332', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434337', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434342', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434352', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434357', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434362', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434367', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434372', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434377', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434382', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434387', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434392', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434397', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434407', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434412', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434417', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434422', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434427', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434437', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434442', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434447', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434452', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434457', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434462', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434467', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434472', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434477', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434482', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434487', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434492', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434497', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434502', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434507', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434512', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434517', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434522', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434527', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434532', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434537', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434542', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434547', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434552', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434557', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434567', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434572', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434577', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434582', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434587', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434592', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434602', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434607', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434612', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434617', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434622', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434627', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434632', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434637', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434642', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434647', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434652', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434657', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434662', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434667', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434672', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434677', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434682', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434687', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434692', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434697', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434702', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434707', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434712', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434717', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434722', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434727', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434732', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434737', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434742', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_434562', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434402', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434322', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434282', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434262', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434252', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434247', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434597', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434432', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434347', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434302', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434277', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434267', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434257', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'syns_list': "['BN-200 HYDROCHLORIDE', 'CG-5503 HYDROCHLORIDE', 'CG5503 HYDROCHLORIDETapentadol hcl', 'Tapentadol hydrochloride']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1876 | Q34 | What are the names of the genes that are targeted by the drug Ivabradine Hydrochloride in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Ivabradine Hydrochloride targets the gene hyperpolarization activated cyclic nucleotide gated potassium channel 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%ivabradine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%ivabradine hydrochloride%" OR LOWER(syns_list) LIKE "%ivabradine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148359', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148365', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148367', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148369', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148373', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148375', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148377', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148381', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148383', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148385', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148387', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148363', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148355', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148351', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148349', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148379', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148371', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148361', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148357', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148353', 'drugName': 'Ivabradine Hydrochloride', 'tradeNames_list': "['Corlanor', 'Procoralan']", 'syns_list': "['AMG 998', 'AMG-998', 'Corlentor', 'Ivabradine', 'Ivabradine hclIvabradine hydrochloride', 'S 16257', 'S-16257-2']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'HCN4', 'approvedName': 'hyperpolarization activated cyclic nucleotide gated potassium channel 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.279 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Furoate in the treatment of Rhinitis, Allergic, Perennial? | In the context of Rhinitis, Allergic, Perennial, the drug Fluticasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rhinitis, allergic, perennial%" OR LOWER(efo_term) LIKE "%rhinitis, allergic, perennial%") AND (LOWER(drugName) LIKE "%fluticasone furoate%" OR LOWER(tradeNames_list) LIKE "%fluticasone furoate%" OR LOWER(syns_list) LIKE "%fluticasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225662', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225689', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225698', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225707', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225725', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225734', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225743', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225761', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225770', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225779', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225788', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225806', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225815', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225824', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225833', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225842', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225851', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225860', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225869', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225878', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225887', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225905', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225914', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225923', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225932', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225941', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225959', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225968', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225977', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225986', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225995', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226004', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226013', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226022', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226031', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226040', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226049', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226058', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226067', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226076', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226085', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226094', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226103', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225896', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225752', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225680', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225644', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225626', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225617', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225950', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225797', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225716', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225671', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225653', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225635', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1830 | Q34 | What are the names of the genes that are targeted by the drug Cyclosporine in the treatment of eye disease? | In the context of eye disease, the drug Cyclosporine targets the gene peptidylprolyl isomerase A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye disease%" OR LOWER(efo_term) LIKE "%eye disease%") AND (LOWER(drugName) LIKE "%cyclosporine%" OR LOWER(tradeNames_list) LIKE "%cyclosporine%" OR LOWER(syns_list) LIKE "%cyclosporine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1101283', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101664', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101791', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101918', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102172', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102299', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102426', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102680', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102807', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102934', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1103061', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101537', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101029', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100775', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100648', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102553', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102045', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101410', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101156', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100902', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.360 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of emphysema? | In the context of emphysema, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%emphysema%" OR LOWER(efo_term) LIKE "%emphysema%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232530', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232611', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232638', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232665', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232719', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232746', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232773', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232827', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232854', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232881', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232908', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232962', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232989', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233016', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233043', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233070', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233097', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233124', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233151', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233178', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233205', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233259', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233286', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233313', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233340', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233367', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233421', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233448', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233475', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233502', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233529', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233556', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233583', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233610', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233637', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233664', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233691', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233718', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233745', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233772', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233799', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233826', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233853', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233880', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233907', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233934', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233961', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233988', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234015', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234042', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234069', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234123', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234150', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234177', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234204', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234231', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234258', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234312', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234339', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234366', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234393', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234420', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234447', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234474', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234501', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234528', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234555', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234582', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234609', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234636', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234663', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234690', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234717', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234744', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234771', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234798', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234825', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234852', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234879', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234906', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234933', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234960', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234987', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235014', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235041', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235068', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234096', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233232', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232800', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232584', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232476', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232422', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232395', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234285', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233394', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232935', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232692', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232557', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232503', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232449', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1099 | Q34 | What are the names of the genes that are targeted by the drug Testosterone in the treatment of orchitis? | In the context of orchitis, the drug Testosterone targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%orchitis%" OR LOWER(efo_term) LIKE "%orchitis%") AND (LOWER(drugName) LIKE "%testosterone%" OR LOWER(tradeNames_list) LIKE "%testosterone%" OR LOWER(syns_list) LIKE "%testosterone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_922026', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922065', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922078', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922091', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922117', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922130', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922143', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922169', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922182', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922195', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922208', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922234', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922247', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922260', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922273', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922286', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922299', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922312', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922325', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922338', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922351', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922377', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922390', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922403', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922416', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922429', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922455', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922468', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922481', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922494', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922526', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922562', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922598', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922634', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922670', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922706', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922742', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922778', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922814', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922850', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922886', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922922', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922958', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922994', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923030', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923066', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923102', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923138', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923174', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923210', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923246', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923318', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923354', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923390', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923426', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923462', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923498', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923570', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923606', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923642', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923678', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923714', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923750', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923786', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923822', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923858', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923894', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923930', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923966', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924002', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924038', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924074', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924110', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924146', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924182', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924218', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924254', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924290', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924326', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924362', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923282', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922364', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922156', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922052', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922000', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921974', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921014', 'drugName': 'Testosterone Cypionate', 'tradeNames_list': "['Andro-Cyp', 'Depandro', 'Depo-testosterone', 'Depotest', 'TestosteroneTestosterone cypionate']", 'syns_list': "['Depo-Testadiol', 'NSC-9157Testosterone 17.beta.-cyclopentanepropionate', 'Testosterone cipionateTestosterone cyclopentylpropionate', 'Testosterone cypionateTestosterone cypionate ciii']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923534', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922442', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922221', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922104', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922039', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922013', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921987', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Orchitis', 'efo_term': 'orchitis', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.238 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of injury? | In the context of injury, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%injury%" OR LOWER(efo_term) LIKE "%injury%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222003', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221938', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222328', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222198', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221873', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222263', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222068', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222133', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222121', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222186', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222316', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221991', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221926', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221861', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222251', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222056', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Eye Injuries', 'efo_term': 'eye injury', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.555 | Q34 | What are the names of the genes that are targeted by the drug Oxcarbazepine in the treatment of epilepsy? | In the context of epilepsy, the drug Oxcarbazepine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy%" OR LOWER(efo_term) LIKE "%epilepsy%") AND (LOWER(drugName) LIKE "%oxcarbazepine%" OR LOWER(tradeNames_list) LIKE "%oxcarbazepine%" OR LOWER(syns_list) LIKE "%oxcarbazepine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_633093', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632553', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632901', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632649', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632433', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633201', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632481', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632529', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632805', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632577', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632925', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632985', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632673', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633141', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632421', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633153', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632445', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633225', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632469', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633237', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632493', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632517', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632757', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632541', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632829', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632565', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632589', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632973', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632613', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632937', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632637', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633009', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632661', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633021', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632685', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633189', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632709', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633129', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632193', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633177', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632277', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633165', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632157', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633285', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632289', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633213', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632205', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633273', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632301', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633261', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633249', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632313', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632733', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632217', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632781', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632325', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632769', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632877', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632337', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632817', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632229', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632865', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632349', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632853', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632145', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633069', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632361', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632913', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632241', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632961', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632373', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632949', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632181', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633057', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632385', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632997', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632253', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633045', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632397', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633033', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632133', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633297', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632409', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633105', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632265', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633321', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633309', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633081', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632889', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632793', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632745', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632721', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632505', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632169', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632841', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632625', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633117', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632457', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632601', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632697', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1853 | Q34 | What are the names of the genes that are targeted by the drug Rosuvastatin Calcium in the treatment of Hypercholesterolemia? | In the context of Hypercholesterolemia, the drug Rosuvastatin Calcium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypercholesterolemia%" OR LOWER(efo_term) LIKE "%hypercholesterolemia%") AND (LOWER(drugName) LIKE "%rosuvastatin calcium%" OR LOWER(tradeNames_list) LIKE "%rosuvastatin calcium%" OR LOWER(syns_list) LIKE "%rosuvastatin calcium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104167', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104198', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104201', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104215', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104232', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104235', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104249', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104252', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104184', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104150', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104133', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104130', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104218', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104181', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104164', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104147', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypercholesterolemia', 'efo_term': 'Hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.865 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of arthritis? | In the context of arthritis, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthritis%" OR LOWER(efo_term) LIKE "%arthritis%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833964', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833807', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834435', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834906', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835377', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835220', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835534', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833650', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834592', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835063', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835691', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835848', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834121', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836005', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834749', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834278', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834257', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834885', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835042', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834414', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835199', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835356', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835984', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833786', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834571', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835513', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835670', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833943', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833629', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834100', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835827', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834728', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.210 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of lateral epicondylitis? | In the context of lateral epicondylitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lateral epicondylitis%" OR LOWER(efo_term) LIKE "%lateral epicondylitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218716', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219340', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219548', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219756', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220172', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220380', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220588', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220796', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219132', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218300', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217884', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217676', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219964', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218924', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218508', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218092', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1371 | Q34 | What are the names of the genes that are targeted by the drug Zanubrutinib in the treatment of Mantle cell lymphoma? | In the context of Mantle cell lymphoma, the drug Zanubrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mantle cell lymphoma%" OR LOWER(efo_term) LIKE "%mantle cell lymphoma%") AND (LOWER(drugName) LIKE "%zanubrutinib%" OR LOWER(tradeNames_list) LIKE "%zanubrutinib%" OR LOWER(syns_list) LIKE "%zanubrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025175', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025226', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025243', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025209', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025107', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025090', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025141', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025192', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025158', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025124', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1727 | Q34 | What are the names of the genes that are targeted by the drug Tafamidis in the treatment of AL amyloidosis? | In the context of AL amyloidosis, the drug Tafamidis targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%al amyloidosis%" OR LOWER(efo_term) LIKE "%al amyloidosis%") AND (LOWER(drugName) LIKE "%tafamidis%" OR LOWER(tradeNames_list) LIKE "%tafamidis%" OR LOWER(syns_list) LIKE "%tafamidis%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097617', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097631', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097636', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097641', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097609', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097601', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097597', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097626', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097621', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097613', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097605', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis, Familial', 'efo_term': 'AL amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.59 | Q34 | What are the names of the genes that are targeted by the drug Lurasidone in the treatment of psychosis? | In the context of psychosis, the drug Lurasidone targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%lurasidone%" OR LOWER(tradeNames_list) LIKE "%lurasidone%" OR LOWER(syns_list) LIKE "%lurasidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_198424', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198448', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198456', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198464', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198480', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198488', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198496', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198512', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198520', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198528', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198536', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198552', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198560', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198568', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198576', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198584', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198592', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198600', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198608', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198616', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198624', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198640', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198648', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198656', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198664', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198672', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198688', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198696', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198704', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198712', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198720', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198728', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198736', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198744', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198752', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198760', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198768', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198776', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198784', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198792', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198800', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198808', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198816', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198824', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198832', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198840', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198848', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198856', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198864', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198872', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198880', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198896', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198904', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198912', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198920', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198928', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198936', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198952', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198960', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198968', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198976', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198984', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198992', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199000', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199008', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199016', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199024', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199032', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199040', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199048', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199056', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199064', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199072', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199080', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199088', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199096', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199104', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199112', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199120', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199128', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199136', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199144', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199152', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199160', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199168', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199176', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198888', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198632', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198504', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198440', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198408', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198392', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198384', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198944', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198680', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198544', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198472', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198432', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198416', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198400', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1570 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of astrocytoma? | In the context of astrocytoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%astrocytoma%" OR LOWER(efo_term) LIKE "%astrocytoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1088075', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084970', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087535', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085230', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085088', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086725', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085365', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085105', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087265', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085500', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088605', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087805', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085635', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089010', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085240', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086590', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085770', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089145', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085358', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086860', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085905', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085375', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087130', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086040', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088463', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085493', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086175', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088733', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085510', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087670', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086310', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088740', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085628', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087940', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086445', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089138', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085645', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086573', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086580', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089020', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085763', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086708', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086715', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089273', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085780', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086843', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086850', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089155', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085898', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086978', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086985', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085915', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087113', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087120', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088335', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086033', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087248', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088480', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086050', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087383', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087390', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088470', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086168', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087518', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087525', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088875', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086185', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087653', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087660', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088615', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086303', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087788', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087795', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088868', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086320', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087923', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087930', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088750', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086438', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088058', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088065', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089280', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086455', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088193', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088200', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089408', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089290', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088885', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088598', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088345', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088328', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088210', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086995', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087255', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087400', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'subependymal giant cell astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085223', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089003', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085095', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084953', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084960', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1843 | Q34 | What are the names of the genes that are targeted by the drug Simvastatin in the treatment of Abnormal circulating lipid concentration? | In the context of Abnormal circulating lipid concentration, the drug Simvastatin targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%abnormal circulating lipid concentration%" OR LOWER(efo_term) LIKE "%abnormal circulating lipid concentration%") AND (LOWER(drugName) LIKE "%simvastatin%" OR LOWER(tradeNames_list) LIKE "%simvastatin%" OR LOWER(syns_list) LIKE "%simvastatin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103894', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103790', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104102', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103998', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1563 | Q34 | What are the names of the genes that are targeted by the drug Bosentan in the treatment of hypertension? | In the context of hypertension, the drug Bosentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%bosentan%" OR LOWER(tradeNames_list) LIKE "%bosentan%" OR LOWER(syns_list) LIKE "%bosentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084233', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084237', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084238', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084261', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084263', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084265', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084266', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084290', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084291', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084293', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084294', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084235', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084209', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084206', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084205', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084289', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084262', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084234', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084210', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084207', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'syns_list': "['Anhydrous bosentan', 'Bosentan', 'Bosentan anhydrous', 'Bosentan hydrateBosentan monohydrate', 'RO 47-0203/029', 'RO-47-0203-029', 'RO-470203029']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.365 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of Nasal Cavity Polyp? | In the context of Nasal Cavity Polyp, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal cavity polyp%" OR LOWER(efo_term) LIKE "%nasal cavity polyp%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232535', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232616', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232643', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232670', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232724', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232751', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232778', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232832', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232859', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232886', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232913', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232967', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232994', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233021', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233048', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233075', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233102', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233129', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233156', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233183', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233210', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233264', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233291', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233318', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233345', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233372', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233426', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233453', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233480', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233507', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233534', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233561', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233588', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233615', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233642', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233669', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233696', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233723', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233750', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233777', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233804', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233831', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233858', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233885', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233912', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233939', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233966', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233993', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234020', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234047', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234074', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234128', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234155', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234182', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234209', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234236', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234263', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234317', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234344', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234371', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234398', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234425', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234452', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234479', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234506', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234533', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234560', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234587', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234614', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234641', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234668', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234695', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234722', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234749', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234776', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234803', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234830', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234857', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234884', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234911', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234938', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234965', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234992', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235019', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235046', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235073', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234101', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233237', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232805', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232589', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232481', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232427', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232400', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234290', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233399', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232940', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232697', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232562', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232508', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232454', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.509 | Q34 | What are the names of the genes that are targeted by the drug Doxepin Hydrochloride in the treatment of alcohol dependence? | In the context of alcohol dependence, the drug Doxepin Hydrochloride targets the gene solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%alcohol dependence%" OR LOWER(efo_term) LIKE "%alcohol dependence%") AND (LOWER(drugName) LIKE "%doxepin hydrochloride%" OR LOWER(tradeNames_list) LIKE "%doxepin hydrochloride%" OR LOWER(syns_list) LIKE "%doxepin hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_440818', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440842', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440850', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440858', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440874', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440882', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440890', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440906', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440914', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440922', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440930', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440946', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440954', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440962', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440970', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440978', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440986', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440994', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441002', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_441010', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440898', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440834', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440802', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440786', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440778', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440938', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440866', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440826', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440810', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_440794', 'drugName': 'Doxepin Hydrochloride', 'tradeNames_list': "['Adapin', 'Doxepin hydrochloride', 'Quitaxon', 'Silenor', 'Sinequan', 'XepinZonalon']", 'syns_list': "['Doxepin hcl', 'Doxepin hydrochloride', 'NSC-108160', 'P-3693A']", 'yearOfFirstApproval': 1969, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alcoholism', 'efo_term': 'alcohol dependence', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1145 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of hepatocellular carcinoma? | Trametinib has not been approved by the FDA as a treatment for hepatocellular carcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hepatocellular carcinoma%" OR LOWER(efo_term) LIKE "%hepatocellular carcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928693', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928813', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928853', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928893', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928973', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929013', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929053', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929133', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929173', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929213', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929253', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929333', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929373', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929413', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929453', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929493', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929533', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929573', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929613', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929653', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929693', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929773', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929813', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929853', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929893', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929933', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930013', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930053', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930093', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930133', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930173', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930213', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930253', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930293', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930333', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930373', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930413', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930453', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930493', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930533', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930573', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930613', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930653', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930693', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930733', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930773', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930813', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930853', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930893', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930933', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930973', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931053', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931093', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931133', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931173', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931213', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931253', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931333', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931373', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931413', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931453', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931493', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931533', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931573', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931613', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931653', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931693', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931733', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931773', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931813', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931853', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931893', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931933', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931973', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932013', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932053', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932093', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932133', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932173', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932213', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932253', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932293', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932333', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932373', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932413', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932453', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931013', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929733', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929093', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928773', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928613', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928533', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928493', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931293', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929973', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929293', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928933', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928733', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928653', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928573', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Hepatocellular', 'efo_term': 'hepatocellular carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1110 | Q34 | What are the names of the genes that are targeted by the drug Tucatinib in the treatment of neoplasm? | In the context of neoplasm, the drug Tucatinib targets the gene erb-b2 receptor tyrosine kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%tucatinib%" OR LOWER(tradeNames_list) LIKE "%tucatinib%" OR LOWER(syns_list) LIKE "%tucatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924451', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924449', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924467', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924477', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924481', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924523', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924465', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924453', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924491', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924454', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924537', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924534', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924478', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924524', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924480', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924522', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924463', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924521', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924494', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924479', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924495', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924493', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924505', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924496', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924468', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924538', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924450', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924506', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924509', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924550', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924508', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924548', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924510', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924466', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924552', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924520', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924519', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924482', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924535', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924551', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924492', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924533', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924452', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924507', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924464', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924547', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924549', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924536', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924546', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924532', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924490', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924504', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924476', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924518', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924462', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924448', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924516', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924461', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924517', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924488', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924530', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924489', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924446', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924474', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924447', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924544', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924545', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924502', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924503', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924460', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924475', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924531', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1589 | Q34 | What are the names of the genes that are targeted by the drug Temsirolimus in the treatment of clear cell renal carcinoma? | In the context of clear cell renal carcinoma, the drug Temsirolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%clear cell renal carcinoma%" OR LOWER(efo_term) LIKE "%clear cell renal carcinoma%") AND (LOWER(drugName) LIKE "%temsirolimus%" OR LOWER(tradeNames_list) LIKE "%temsirolimus%" OR LOWER(syns_list) LIKE "%temsirolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091088', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091313', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091388', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091463', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090938', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090788', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090713', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091238', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091163', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1091013', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090863', 'drugName': 'Temsirolimus', 'tradeNames_list': "['Torisel']", 'syns_list': "['CCI-779', 'Temsirolimus']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1572 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of cancer? | In the context of cancer, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1087385', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086049', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090625', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086319', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086859', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090220', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085239', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086710', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087925', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084955', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086305', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086589', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086454', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090355', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089410', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089950', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090234', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090639', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086845', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086575', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086980', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085509', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087399', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087520', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088195', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087939', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085090', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089140', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084969', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088749', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088870', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089289', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085644', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088884', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089424', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089694', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090490', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086440', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086724', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085630', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090369', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090504', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089964', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085374', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090085', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089545', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085225', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089275', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086994', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089154', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089680', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086035', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087250', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087129', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087669', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085914', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087655', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088479', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087804', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088074', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088060', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088465', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088209', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088344', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085360', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089815', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085104', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086184', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086170', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089019', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088735', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089005', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085495', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089829', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088600', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087790', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087264', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087115', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085900', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085779', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089559', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087534', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088330', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088614', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090099', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085765', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086837', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086836', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086838', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085215', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085216', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085217', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086972', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087105', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085218', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086971', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084945', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085758', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085757', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086973', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.813 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828370', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828472', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828506', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828540', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828438', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828302', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828234', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828200', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828574', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828404', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828336', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828268', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.948 | Q34 | What are the names of the genes that are targeted by the drug Ketorolac Tromethamine in the treatment of cataract? | In the context of cataract, the drug Ketorolac Tromethamine targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cataract%" OR LOWER(efo_term) LIKE "%cataract%") AND (LOWER(drugName) LIKE "%ketorolac tromethamine%" OR LOWER(tradeNames_list) LIKE "%ketorolac tromethamine%" OR LOWER(syns_list) LIKE "%ketorolac tromethamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_841850', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841898', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841914', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841930', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841962', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841978', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841994', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842026', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842042', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842058', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842074', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842106', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842122', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842138', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842154', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842170', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842186', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842202', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842218', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842234', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842250', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842266', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842010', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841882', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841818', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841786', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841770', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842090', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841946', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841866', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841834', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841802', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cataract', 'efo_term': 'cataract', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1232 | Q34 | What are the names of the genes that are targeted by the drug Metoprolol Succinate in the treatment of hypertension? | In the context of hypertension, the drug Metoprolol Succinate targets the gene adrenoceptor beta 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%metoprolol succinate%" OR LOWER(tradeNames_list) LIKE "%metoprolol succinate%" OR LOWER(syns_list) LIKE "%metoprolol succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937656', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937678', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937634', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937612', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937601', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937667', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937645', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_937623', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'syns_list': "['H 93/26 SUCCINATE', 'Metoprolol hemisuccinate', 'Metoprolol succinateSeloken-zok', 'Selozok']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.120 | Q34 | What are the names of the genes that are targeted by the drug Desvenlafaxine in the treatment of unipolar depression? | In the context of unipolar depression, the drug Desvenlafaxine targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%desvenlafaxine%" OR LOWER(tradeNames_list) LIKE "%desvenlafaxine%" OR LOWER(syns_list) LIKE "%desvenlafaxine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206620', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206631', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206632', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206637', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206643', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206644', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206649', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206655', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206656', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206661', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206662', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206668', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206673', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206674', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206679', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206680', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206685', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206686', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206691', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206692', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206697', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206703', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206704', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206709', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206710', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206718', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206732', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206739', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206746', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206753', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206760', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206767', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206774', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206781', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206788', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206795', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206802', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206809', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206816', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206823', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206830', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206837', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206698', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206650', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206626', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206614', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206608', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206607', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206725', 'drugName': 'Desvenlafaxine Succinate', 'tradeNames_list': "['Desvenlafaxine succinate', 'Pristiq']", 'syns_list': "['DVS-233', 'Desvenlafaxine succinate', 'Desvenlafaxine succinate anhydrousDesvenlafaxine succinate hydrate', 'Desvenlafaxine succinate monohydrateDvs anhydrous', 'O-desmethyl venlafaxine succinateO-desmethylvenlafaxine succinate', 'WY-45233', 'WY45233']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206667', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206638', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206625', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206619', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206613', 'drugName': 'Desvenlafaxine', 'tradeNames_list': "['Desvenlafaxine', 'Khedezla', 'Pristiq']", 'syns_list': "['D-veniz', 'Desvenlafaxine', 'Mdd-xr', 'Newven', 'O-desmethylvenlafaxineODV']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1891 | Q34 | What are the names of the genes that are targeted by the drug Torsemide in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Torsemide targets the gene solute carrier family 12 member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%torsemide%" OR LOWER(tradeNames_list) LIKE "%torsemide%" OR LOWER(syns_list) LIKE "%torsemide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149089', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149097', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1014 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of common cold? | In the context of common cold, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%common cold%" OR LOWER(efo_term) LIKE "%common cold%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857480', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.526 | Q34 | What are the names of the genes that are targeted by the drug Fexofenadine Hydrochloride in the treatment of allergic disease? | In the context of allergic disease, the drug Fexofenadine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic disease%" OR LOWER(efo_term) LIKE "%allergic disease%") AND (LOWER(drugName) LIKE "%fexofenadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%fexofenadine hydrochloride%" OR LOWER(syns_list) LIKE "%fexofenadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455786', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455792', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.